Using our in-house tissue microarray with tumor tissue sections obtained from HCC patients who went on for sorafenib treatment, high proteomic AXL expression was tightly associated with worse overall survival, indicative of a prognostic value of AXL in predicting sorafenib treatment response (Suppl. This evidence concerns the gene AXL and hepatocellular carcinoma.